Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 2.45 Million CAD | 39.49% |
| 2023 | 1.61 Million CAD | 37.29% |
| 2022 | 1.17 Million CAD | -43.01% |
| 2021 | 2.05 Million CAD | 68.38% |
| 2020 | 1.22 Million CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | -100.0% |
| 2016 | 2242.00 CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 2.45 Million CAD | -18.38% |
| 2024 FY | 2.45 Million CAD | 52.29% |
| 2024 Q3 | 3 Million CAD | 17.25% |
| 2024 Q1 | 1.76 Million CAD | 9.41% |
| 2024 Q2 | 2.56 Million CAD | 45.45% |
| 2023 FY | 1.61 Million CAD | 37.29% |
| 2023 Q4 | 1.61 Million CAD | 0.86% |
| 2023 Q3 | 1.59 Million CAD | 8.76% |
| 2023 Q2 | 1.46 Million CAD | 33.7% |
| 2023 Q1 | 1.09 Million CAD | -6.39% |
| 2022 Q3 | 1.24 Million CAD | -5.47% |
| 2022 Q4 | 1.17 Million CAD | -5.9% |
| 2022 FY | 1.17 Million CAD | -43.01% |
| 2022 Q1 | 1.38 Million CAD | -32.5% |
| 2022 Q2 | 1.31 Million CAD | -5.09% |
| 2021 Q2 | 1.59 Million CAD | 37.51% |
| 2021 FY | 2.05 Million CAD | 68.38% |
| 2021 Q4 | 2.05 Million CAD | 19.23% |
| 2021 Q3 | 1.72 Million CAD | 8.37% |
| 2021 Q1 | 1.15 Million CAD | -5.23% |
| 2020 Q3 | 1.28 Million CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 Q4 | 1.22 Million CAD | -4.88% |
| 2020 FY | 1.22 Million CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 FY | - CAD | -100.0% |
| 2017 Q1 | 3479.00 CAD | 21.39% |
| 2017 Q2 | - CAD | -100.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | 2242.00 CAD | 0.0% |
| 2016 Q3 | - CAD | -100.0% |
| 2016 Q2 | 2242.00 CAD | 0.0% |
| 2016 Q4 | 2866.00 CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -27.463% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.045% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -510.596% |
| SQZ Biotechnologies Company | 27.47 Million USD | 91.068% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -5.491% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.343% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 91.757% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -158.752% |
| Marizyme, Inc. | 18.71 Million USD | 86.891% |
| Genus plc | 233.1 Million USD | 98.947% |
| Pharming Group N.V. | 171.54 Million USD | 98.57% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -176.295% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -82.621% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -227.156% |
| ContraFect Corporation | 2.88 Million USD | 14.833% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -69.649% |
| IMV Inc. | 28.88 Million USD | 91.505% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 56.636% |
| ONE Bio Corp. | 19.71 Million USD | 87.554% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 95.732% |
| Mesoblast Limited | 118.7 Million USD | 97.933% |
| MultiCell Technologies, Inc. | 202.58 USD | -1211111.373% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 92.587% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.413% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -289.424% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -99.752% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 40.473% |
| Biomind Labs Inc. | 735.54 Thousand USD | -233.587% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 18.919% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 81.121% |
| Skye Bioscience, Inc. | 4.61 Million USD | 46.836% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -582.125% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 16.268% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1633.823% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1711.002% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 58.208% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -9440.309% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -64.153% |
| Q BioMed Inc. | 4.1 Million USD | 40.3% |
| GB Sciences, Inc. | 1.75 Million USD | -39.468% |
| Alpha Cognition Inc. | 1.22 Million USD | -101.059% |
| CSL Limited | 12.18 Billion USD | 99.98% |
| Agentix Corp. | 50 Thousand USD | -4807.344% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.373% |
| Enzolytics Inc. | 996.33 Thousand USD | -146.269% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 62.199% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -859.996% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -8.647% |
| argenx SE | 20 Million USD | 87.732% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 94.614% |
| HST Global, Inc. | 98.31 Thousand USD | -2395.623% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -886.52% |
| Halberd Corporation | 150 Thousand USD | -1535.781% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 65.308% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -23896.792% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 9.415% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -2.333% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -970.113% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1550.593% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1123.069% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -11.537% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 87.93% |
| Kadimastem Ltd | 891.22 Thousand USD | -175.314% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 47.921% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -880.755% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -7201.291% |
| Cell Source, Inc. | 9.25 Million USD | 73.486% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -224.472% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -224.472% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -406.66% |
| Itoco Inc. | 228.37 Thousand USD | -974.395% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1063.016% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 50.759% |
| International Stem Cell Corporation | 4.17 Million USD | 41.272% |
| CytoDyn Inc. | 30.07 Million USD | 91.842% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -597.369% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 68.623% |
| SYBLEU INC | 477.5 Thousand USD | -413.858% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1902.998% |
| Rebus Holdings, Inc. | 310 Thousand USD | -691.507% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 48.183% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3831.348% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -12.507% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 70.495% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 71.419% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -57.744% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -815.549% |
| Neutra Corp. | 54.15 Thousand USD | -4430.748% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -34.08% |
| PureTech Health plc | 25.51 Million USD | 90.382% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -100.426% |
| IXICO plc | 472.02 Thousand USD | -419.82% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 84.171% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.059% |
| CSL Limited | 12.18 Billion USD | 99.98% |
| Cellectis S.A. | 92.77 Million USD | 97.355% |